Novartis canakinumab (ACZ885) reduced cardiovascular risk by 25 percent in subgroup of CANTOS Phase III trial participants. Novartis announced results from a new analysis of the Phase III CANTOS study presented by Dr. Paul Ridker at the American Heart Association (AHA) Scientific Sessions 2017 and published simultaneously in The Lancet.1 The pre-planned secondary analysis of an exploratory endpoint showed…
Novartis Drug Delivers Superior Reductions In Retinal Thickness During Trial
Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness. Novartis has announced further positive results from two Phase III studies of brolucizumab versus aflibercept. Results showed non-inferiority in primary endpoint, superiority in key retinal health outcomes, and long-lasting effect in patients with neovascular…
Psoriatic Arthritis Symptoms Reduced In Novartis Cosentyx Study
Novartis announces study data demonstrating Cosentyx reduced signs and symptoms of psoriatic arthritis while inhibiting progression of joint structural damage. Novartis announced results from the FUTURE 5 study showing Cosentyx (secukinumab) reduced the signs and symptoms of psoriatic arthritis (PsA) while significantly inhibiting the progression of joint structural damage in PsA patients compared to placebo at…
Novartis Plans $3.9B Acquisition Of Advanced Accelerator Applications
Novartis Receives FDA Approval for Expanded Use of Zykadia
Novartis Reports Sales Growth, but Net Income Off 17 Percent in Q1
Novartis Drug Improves Responses in Severe Aplastic Anemia
CAR-T Cell Therapy Receives FDA Breakthrough Designation
Novartis CAR-T cell therapy CTL019 receives FDA Breakthrough Therapy designation for treatment of adult patients with r/r DLBCL. Novartis announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to CTL019, an investigational chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of adult patients with relapsed and refractory (r/r)…
